On this page
Overview
Product & regulatory status
FDA-approved oral prescription drug for female ovulatory dysfunction. Male hypogonadism use is off label.
Estrogen-feedback modulation
Clomiphene alters estrogen feedback and can increase pituitary gonadotropin signalling. Its effects depend on the functioning reproductive axis. [1]
What the evidence shows
Approved clinical context
The Clomid label summarizes clinical investigations in 7,578 patients, with pregnancies in approximately 30%. This historical overall result includes varied infertility circumstances and cannot predict an individual’s chance of conception or live birth. [1]
Male trial with important limits
A 12-week placebo-controlled trial in 78 men with obesity-associated secondary hypogonadism found increased testosterone and improved body-composition measures. One sexual complaint improved, but HDL cholesterol fell; the trial did not establish long-term fertility or cardiovascular outcomes. [2]
What remains unknown
Response depends on the cause of reproductive dysfunction. A hormone increase is not proof of restored fertility or an explanation for every symptom.
Safety
Visual symptoms
The label warns of blurred vision, flashes and other visual disturbances, occasionally prolonged or irreversible. These require prompt clinical review. [1]
Ovarian treatment risks
Ovarian enlargement, hyperstimulation and multiple pregnancy are relevant to ovulation induction; they are not the same risk context as treatment in men. [1]
Match the indication
Evidence for an oral prescription tablet used for ovulatory dysfunction does not make off-label male treatment an approved indication. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is clomiphene interchangeable with enclomiphene?
No. Clomiphene includes enclomiphene and zuclomiphene, which have different pharmacologic properties.
What should I ask about follow-up?
Which clinical outcome matters—ovulation, symptoms or fertility—and how benefit and adverse effects will be checked.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Clomid prescribing informationUS clomiphene citrate label; female ovulatory-dysfunction indication, visual adverse effects and ovarian risks.
- Soares et al.: clomiphene in male obesity-associated hypogonadismInternational Journal of Obesity, 2018; randomized double-blind placebo-controlled trial, 78 men, 12 weeks.
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.